Prelude Therapeutics (PRLD) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 8, 2026.

Voting matters and shareholder proposals

• Election of three Class III directors: Krishna Vaddi, Paul Scherer, and Katina Dorton, with board recommending a vote in favor.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve 2025 executive compensation (say-on-pay).

• Advisory vote on the frequency of future say-on-pay votes.

• Other business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Board recommends all director nominees for election to Class III positions.